StockData
Cypherpunk Technologies Inc. logo

Cypherpunk Technologies Inc. (CYPH) company profile

CYPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026Score 4/30
$1.87−0.07 (-3.86%)

Close on Nov 13, 2026Market cap $201.52MP/E –Yield –

About Cypherpunk Technologies

Pharmaceutical Preparations, SIC 2834

Cypherpunk Technologies Inc. is a privacy technology company focused on advancing privacy-preserving infrastructure for the digital economy and developing novel therapies for cancer patients. The company operates two primary segments: its privacy technology business and its biotechnology subsidiary, Leap Therapeutics, Inc. Within its privacy division, the company identifies, develops, and invests in privacy-enhancing technologies, anchored by a digital asset treasury strategy focused on the Zcash network and its native cryptocurrency, ZEC. Through Leap Therapeutics, it researches and develops biomarker-targeted antibody therapies, primarily sirexatamab for colorectal and other cancers, as well as a preclinical antibody program, FL-501, for cachexia. The company serves oncology patients through its therapeutic pipeline while targeting users and participants within the decentralized digital economy.

The company conducts its biotechnology operations through wholly owned subsidiaries in the United States and Australia, including HealthCare Pharmaceuticals Pty Ltd. Cypherpunk Technologies Inc. is incorporated in the state of Delaware, with its primary corporate identity rooted in the United States.

Summary of the business section of Cypherpunk Technologies's latest annual report, written by StockData.

Company profile

Company

Legal name
Cypherpunk Technologies Inc.
Founded
2011
Headquarters
Cambridge, MA
Address
47 Thorndike Street, Suite B1-1 02142
Phone
(617) 252-4343
Employees
6, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
EisnerAmper LLP, Philadelphia, Pennsylvania

Stock & identifiers

Ticker
CYPH
Former tickers
LPTX until Nov 18, 2025
Exchange
Nasdaq
IPO date
Jan 25, 2017
Shares outstanding
108M, Aug 10, 2026
Public float
$12.10M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-10 reverse, Jun 21, 2023
SEC CIK
1509745
CUSIP
52187K200
ISIN
US52187K2006
FIGI
BBG00DQ929W6
Share class FIGI
BBG00DQ929Z3
LEI
549300T31SMMJ2DDLI13
EIN
27-4412575

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
William Patrick McEvoy IIIChief Investment Officer, Director29,793,414
Douglas E. OnsiCEO,CFO,Pres.,GC,Treas.&Sec., Director106,858
Kevin ZhangHead of Mining330,904
John Mark O'MahonyChief Manufacturing Officer27,500
Augustine LawlorChief Operating Officer706,042
Jason BaumChief Scientific Officer15,896
Christine GranfieldVP, Head of Reg Affairs/Qual22,500
Cynthia SirardChief Medical Officer27,500
Patricia A. MartinDirector118,750
Khing Djien OeiDirector0
Amanda FabianoDirector–
Thomas John DietzDirector132,500
Nissim MashiachDirector168,750
William LiDirector74,700
Christian M. RichardDirector74,700
Christopher MirabelliDirector130,376
Richard SchilskyDirector74,700
James H. CavanaughDirector168,963
Joseph LoscalzoDirector168,750

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$4.75M$5.50M$3.76M$26–
FY2024$1.48M$1.22M$1.04M$64–
FY2023$1.53M$1.67M$1.00M$92–
FY2022$1.88M-$1.62M$1.36M$14–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Douglas E. Onsi
Chief Executive Officer, Chief Financial Officer, Treasurer and Secretary
$708.75K$3.98M$0$54.32K$4.74M+224%
William McEvoy
Chief Investment Officer
$35.42K$6.63M$0–$6.66M–
Cynthia Sirard
Former Chief Medical Officer
$306.25K$0$43.75K$287.68K$637.68K-44%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 6 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?